HPV2 vaccinees were evaluated for injection-site and systemic symptoms, medically significant conditions, new onset autoimmune disorders, new onset chronic diseases, deaths, serious adverse events, and pregnancy outcomes. Safety was evaluated by pooling data from 11 clinical trials of bivalent vaccine in females aged 10 through 25 years,9 and by a meta-analysis of safety databases of bivalent vaccine as well as other vaccines with the same adjuvant.10 The pooled safety analysis included 23,713 females aged 10 through 25 years; approximately 12,000 females received at least 1 dose of HPV2. In an analysis of local and general adverse events, a larger proportion of persons reported at least one injection-site symptom in the HPV2 group compared with controls.5 In the HPV2 group, 92% reported injection-site pain, 48% redness, and 44% swelling compared with 64%-87%, 24%-28%, and 17%-21% in the control groups. Fatigue, headache, and myalgia were the most common general symptoms. No differences were observed in unsolicited symptoms within 30 days of vaccination between the vaccine group and control groups.